Published in Adv Anat Pathol on March 01, 2010
miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions. Br J Cancer (2011) 0.99
Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival. PLoS One (2011) 0.94
Intracranial melanocytic meningeal tumours and melanosis oculi: case report and literature review. BMC Cancer (2012) 0.80
Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi. Mod Pathol (2016) 0.79
Differentiation of pigmented Spitz nevi and Reed nevi by integration of dermatopathologic and dermatoscopic findings. Dermatol Pract Concept (2012) 0.76
Atypical cellular blue nevus or malignant blue nevus? An Bras Dermatol (2017) 0.75
Oral atypical cellular blue nevus: an infiltrative melanocytic proliferation. Head Neck Pathol (2012) 0.75
Variation among pathologists' treatment suggestions for melanocytic lesions: A survey of pathologists. J Am Acad Dermatol (2016) 0.75
"Indeterminate biological malignant potential" cannot be used like a synonym of "uncertain malignant potential". Adv Anat Pathol (2012) 0.75
Junctional spitz tumor (nevus) of the upper lip. Head Neck Pathol (2013) 0.75
[Dysplastic melanocytic nevus]. Pathologe (2015) 0.75
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 16.87
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell (2008) 9.22
Melanoma. N Engl J Med (2006) 8.80
The essence of senescence. Genes Dev (2010) 8.21
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 7.18
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res (2011) 4.70
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med (2015) 4.64
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol (2003) 4.15
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Excision margins in high-risk malignant melanoma. N Engl J Med (2004) 3.94
Cutaneous melanoma. Lancet (2005) 3.94
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet (2009) 3.89
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol (2009) 3.64
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. J Cutan Pathol (2004) 3.43
Leukemia cutis. Am J Clin Pathol (2008) 3.38
Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell (2003) 3.31
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol (2012) 3.24
Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res (2008) 3.24
The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol (2004) 2.99
Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J Clin Oncol (2009) 2.85
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood (2007) 2.82
Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol (2003) 2.81
ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell (2011) 2.77
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov (2014) 2.74
Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet (2009) 2.65
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol (2006) 2.62
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol (2011) 2.62
Nevus/Melanocytoma/Melanoma: an emerging paradigm for classification of melanocytic neoplasms? Arch Pathol Lab Med (2011) 2.60
Follicular mucinosis: a critical reappraisal of clinicopathologic features and association with mycosis fungoides and Sézary syndrome. Arch Dermatol (2002) 2.53
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res (2012) 2.46
Temporal dissection of tumorigenesis in primary cancers. Cancer Discov (2011) 2.40
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
De novo intraepidermal epithelioid melanocytic dysplasia as a marker of the atypical mole phenotype -- a clinical and pathological study of 75 patients. J Cutan Pathol (2005) 2.38
An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature (2012) 2.35
Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol (2002) 2.35
An atypical melanocytic lesion without genomic abnormalities shows locoregional metastasis. J Cutan Pathol (2012) 2.31
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Pigmented epithelioid melanocytoma: a low-grade melanocytic tumor with metastatic potential indistinguishable from animal-type melanoma and epithelioid blue nevus. Am J Surg Pathol (2004) 2.29
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy. Melanoma Res (2009) 2.26
Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol (2005) 2.25
Pyoderma gangrenosum: a review. J Cutan Pathol (2003) 2.23
Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol (2005) 2.22
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res (2009) 2.21
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer (2009) 2.20
BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol (2012) 2.17
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin. J Cutan Pathol (2007) 2.14
Increasing tumor thickness is associated with recurrence and poorer survival in patients with Merkel cell carcinoma. Ann Surg Oncol (2012) 2.13
Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol (2005) 2.12
Cutaneous metastases from internal malignancies: a clinicopathologic and immunohistochemical review. Am J Dermatopathol (2012) 2.11
The performance of MelaFind: a prospective multicenter study. Arch Dermatol (2010) 2.07
Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol (2007) 2.06
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev (2012) 2.06
Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol (2010) 2.06
Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol (2006) 2.05
Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev (2004) 2.05
Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol (2003) 2.05
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res (2009) 2.03
Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. J Clin Oncol (2013) 2.00
Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat Genet (2002) 2.00
A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res (2005) 1.95
Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet (2013) 1.95
Unusual variants of malignant melanoma. Mod Pathol (2006) 1.93
Dermoscopy in general dermatology. Dermatology (2006) 1.92
Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol (2012) 1.90
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res (2014) 1.89
Pigmented lesions of the oral mucosa and perioral tissues: a flow-chart for the diagnosis and some recommendations for the management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2008) 1.88
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A (2013) 1.88
Diagnostic applicability of in vivo confocal laser scanning microscopy in melanocytic skin tumors. J Invest Dermatol (2005) 1.88
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87
Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol (2009) 1.87
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol (2005) 1.84
Ambiguous melanocytic tumors with loss of 3p21. Am J Surg Pathol (2014) 1.83
Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas. Am J Surg Pathol (2009) 1.82
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol (2013) 1.80
In vivo confocal microscopy for diagnosis of melanoma and basal cell carcinoma using a two-step method: analysis of 710 consecutive clinically equivocal cases. J Invest Dermatol (2012) 1.79
Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). Arch Dermatol (2008) 1.78